Sleep reactivity predicts insomnia in patients diagnosed with breast cancer
Recommended Citation
Rehman A, Drake CL, Shiramizu V, and Fleming L. Sleep reactivity predicts insomnia in patients diagnosed with breast cancer. J Clin Sleep Med 2022.
Document Type
Article
Publication Date
8-1-2022
Publication Title
J Clin Sleep Med
Abstract
STUDY OBJECTIVES: To examine the role of sleep reactivity as a predictor of insomnia in patients diagnosed with breast cancer.
METHODS: One hundred and seventy three women with breast cancer participated and were followed up over a period of 9 months. At baseline participants were assigned to a high (n=114) or low (n=59) sleep reactivity group, based on their responses to the Ford Insomnia Response to Stress Test (FIRST). We assessed whether these FIRST groupings (high/low sleep reactivity) predicted changes in insomnia over time using the Insomnia Severity Index (ISI). We also tested if these FIRST groupings predicted insomnia disorder (using ISI index cut-offs) at three different time points (T3, T6 and T9).
RESULTS: Individuals with high sleep reactivity were more likely to experience a worsening of insomnia. Using logistic regression we also found that FIRST grouping predicted insomnia disorder. Results remained significant after controlling for estimated pre-morbid sleep, age and whether someone had chemotherapy.
CONCLUSIONS: Our study shows that sleep reactivity may be a robust predictor of insomnia within breast cancer populations. Sleep reactivity should be considered in routine clinical assessments as a reliable way to identify patients at risk of developing insomnia. This would facilitate early sleep intervention for those patients who are considered high risk.
PubMed ID
35912701
ePublication
ePub ahead of print
